Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of Renal Function and Acute Rejection in 0 DR Mis-Matched Renal Allograft Recipients
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 70
- 主要终点
- The primary efficacy endpoint is the renal function, evaluated by 51Cr-EDTA clearance and normalized for 1.73 m2 body-surface, at 12 months posttransplant.
研究概览
简要总结
To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match, receiving immunosuppressive therapy with A) Zenapax® (5 doses), CellCept® (1.5 g bid., aiming for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B) Sandimmun Neoral® (full dose), CellCept® (1.0 g bid.) and prednisolone.
详细描述
Primary Objective To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match, receiving immunosuppressive therapy with A) Zenapax® (5 doses), CellCept® (1.5 g bid., aiming for TDM for total trough concentrations of 2-6 mg/L) and prednisolone or B) Sandimmun Neoral® (full dose), CellCept® (1.0 g bid.) and prednisolone.
Secondary Objectives To compare the two treatment groups with regard to: patient and graft survival (12 months), biopsy-proven and presumptive rejection episodes (3 and 12 months), posttransplant (12 months) incidence and severity of hypertension, hyperlipidemia, glucose intolerance, incidence of infection and tolerability and "success rate" of TDM guided CellCept® dosing in a calcineurin inhibitor-free immunosuppressive protocol over 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Patients of either gender above 18 years of age.
- •Patients who are recipients of primary, 0 DR mis-matched renal allografts from cadaveric donors (aged between 10 and 70 years).
- •3. Patients who are single organ recipients (kidney only).
- •If the patients are women of childbearing potential, they must use safe contraceptives.
- •5. Patients not previously treated with Zenapax® or Simulect®.
- •Patients must be capable to understand the information given about the study, including purpose and risks, and they must sign a statement of informed consent in accordance with the Helsinki declaration.
- •7. Patients with white blood count greater than 2.5 x 109 /L (IU), platelet count greater than 100 x 109 /L (IU) or haemoglobin greater than 6 g/dL at the time of entry into the study.
排除标准
- •1. Patients who are recipients of HLA-identical renal transplants.
- •PRA positive (>20%) patients at any time the alst 6 months.
- •Patients who are unable to stay outside hospital as outpatients for 3 months.
- •4. Patients who are unable to receive oral medication.
- •Patients with active peptic ulcer disease.
- •Patients with active infection.
- •Patients with disorders which might interfere with their ability to absorb oral medication, such as severe diarrhoea or patients with previously diagnosed diabetic gastroenteropathy.
- •8. Patients who are pregnant or nursing mothers.
- •Patients with ongoing malignancies, excluding adequately treated skin carcinoma.
- •10. Patients not able to adhere to the investigational immunosuppressive therapy.
- •11. Patients receiving bile-acid sequestants.
结局指标
主要结局
The primary efficacy endpoint is the renal function, evaluated by 51Cr-EDTA clearance and normalized for 1.73 m2 body-surface, at 12 months posttransplant.
次要结局
- • Combined patient and graft survival at 12 months posttransplant.
- • Incidence and severity of hypertension at 10 weeks and 12 months posttransplant.
- • Proportion of patients with biopsy-proven acute rejection or acute rejection (biopsy proven + presumptive) episode at 3 and 12 month posttransplant.
- • Incidence of glucose intolerance at 10 weeks and 12 months posttransplant.
- • Incidence and severity of dyslipidemia at 10 weeks and 12 months posttransplant.
- • Incidence of treatment failure at 12 months posttransplant.
- • Success rate of TDM guided CellCept® dosing at 3 months posttransplant.
- • Infection rate.